Factors associated with non-response to lactulose therapy in cirrhotic patients with minimal hepatic encephalopathy

Background and objectives: Minimal hepatic encephalopathy (MHE) impairs health related quality of life and predicts overt hepatic encephalopathy (HE) in cirrhotic patients. Lactulose is effective in the treatment of MHE. But the response to lactulose treatment depends on several factors. This study...

Full description

Bibliographic Details
Main Authors: Shireen Ahmed, Md. Golam Azam, Indrajit Kumar Datta, Md. Nazmul Hoque, Tareq M Bhuiyan
Format: Article
Language:English
Published: Ibrahim Medical College 2018-01-01
Series:IMC Journal of Medical Science
Online Access:http://www.imcjms.com/registration/journal_full_text/231
id doaj-64e1d8873fd84699b09c562426e3fdaa
record_format Article
spelling doaj-64e1d8873fd84699b09c562426e3fdaa2020-11-25T00:54:22ZengIbrahim Medical CollegeIMC Journal of Medical Science2519-17212519-15862018-01-011211521Factors associated with non-response to lactulose therapy in cirrhotic patients with minimal hepatic encephalopathyShireen Ahmed0Md. Golam Azam1Indrajit Kumar Datta2Md. Nazmul Hoque3Tareq M Bhuiyan 4Department of Gastroenterology Hepatobiliary and Pancreatic Disorders,BIRDEM General Hospital,122, Kazi Nazrul Islam Avenue, Dhaka-1000Department of Gastroenterology Hepatobiliary and Pancreatic Disorders,BIRDEM General Hospital,122, Kazi Nazrul Islam Avenue, Dhaka-1000Department of Gastroenterology Hepatobiliary and Pancreatic Disorders,BIRDEM General Hospital,122, Kazi Nazrul Islam Avenue, Dhaka-1000Department of Gastroenterology Hepatobiliary and Pancreatic Disorders,BIRDEM General Hospital,122, Kazi Nazrul Islam Avenue, Dhaka-1000Department of Gastroenterology Hepatobiliary and Pancreatic Disorders,BIRDEM General Hospital,122, Kazi Nazrul Islam Avenue, Dhaka-1000Background and objectives: Minimal hepatic encephalopathy (MHE) impairs health related quality of life and predicts overt hepatic encephalopathy (HE) in cirrhotic patients. Lactulose is effective in the treatment of MHE. But the response to lactulose treatment depends on several factors. This study was aimed to find out the contributing factors to non-response to lactulose therapy. Materials and methods: The study was carried out at the BIRDEM general hospital from September, 2013 to March, 2015. Sixty patients were enrolled to assess the response of lactulose therapy in cirrhotic patients with MHE. MHE was diagnosed based on abnormal psychometric tests namely, number connection test (NCT), digit symbol test (DST) and high serum ammonia level. A daily dose of 30-60 ml of lactulose was given to all patients for one month. The response to treatment with regard to MHE was determined after one month using defined criteria. The response was graded as responder and non-responder. Results: The mean age of the study population was 57.0±10.3 years. Out of 60 cases, 46 (77%) were male and 39 (65%) had diabetes. Out of 60 enrolled MHE cases, 16 (27%) had Child-Turcotte-Pugh-A (CTP-A) score and 44 (73%) belonged to CTP-B & C category. Out of 60 MHE cases, 23 (38.3%) showed improvement in their MHE status based on normalization of psychometric tests and reduction of serum ammonia level to ≤32 µmol/L. Age, gender and diabetes were not associated with the response to lactulose therapy. Low baseline arterial pressure was significantly (p=0.003) associated with non-response to lactulose treatment. The mean baseline ammonia level was higher significantly among the non-responders compared to the responders (83.6±21.4 µmol/L vs 58.8±19.8 µmol/L, p<0.001). Compared to responders, low serum sodium and potassium and raised serum bilirubin levels of non-responders at baseline were found significantly (p<0.05) associated with non-response to one month of lactulose treatment. Initial hemoglobulin, peripheral leucocyte and platelet counts did not have any effect on the response to lactulose treatment in MHE cases. Conclusions:The status of MHE in patients with cirrhosis improved by one-month treatment with lactulose. Baseline low arterial pressure, hyperammonemia, hypokalemia and hyponatremia were major contributors to non-response to lactulose therapy. The findings of the study would be useful in treating patients of cirrhosis with MHE. IMC J Med Sci 2018; 12(1): 15-21http://www.imcjms.com/registration/journal_full_text/231
collection DOAJ
language English
format Article
sources DOAJ
author Shireen Ahmed
Md. Golam Azam
Indrajit Kumar Datta
Md. Nazmul Hoque
Tareq M Bhuiyan
spellingShingle Shireen Ahmed
Md. Golam Azam
Indrajit Kumar Datta
Md. Nazmul Hoque
Tareq M Bhuiyan
Factors associated with non-response to lactulose therapy in cirrhotic patients with minimal hepatic encephalopathy
IMC Journal of Medical Science
author_facet Shireen Ahmed
Md. Golam Azam
Indrajit Kumar Datta
Md. Nazmul Hoque
Tareq M Bhuiyan
author_sort Shireen Ahmed
title Factors associated with non-response to lactulose therapy in cirrhotic patients with minimal hepatic encephalopathy
title_short Factors associated with non-response to lactulose therapy in cirrhotic patients with minimal hepatic encephalopathy
title_full Factors associated with non-response to lactulose therapy in cirrhotic patients with minimal hepatic encephalopathy
title_fullStr Factors associated with non-response to lactulose therapy in cirrhotic patients with minimal hepatic encephalopathy
title_full_unstemmed Factors associated with non-response to lactulose therapy in cirrhotic patients with minimal hepatic encephalopathy
title_sort factors associated with non-response to lactulose therapy in cirrhotic patients with minimal hepatic encephalopathy
publisher Ibrahim Medical College
series IMC Journal of Medical Science
issn 2519-1721
2519-1586
publishDate 2018-01-01
description Background and objectives: Minimal hepatic encephalopathy (MHE) impairs health related quality of life and predicts overt hepatic encephalopathy (HE) in cirrhotic patients. Lactulose is effective in the treatment of MHE. But the response to lactulose treatment depends on several factors. This study was aimed to find out the contributing factors to non-response to lactulose therapy. Materials and methods: The study was carried out at the BIRDEM general hospital from September, 2013 to March, 2015. Sixty patients were enrolled to assess the response of lactulose therapy in cirrhotic patients with MHE. MHE was diagnosed based on abnormal psychometric tests namely, number connection test (NCT), digit symbol test (DST) and high serum ammonia level. A daily dose of 30-60 ml of lactulose was given to all patients for one month. The response to treatment with regard to MHE was determined after one month using defined criteria. The response was graded as responder and non-responder. Results: The mean age of the study population was 57.0±10.3 years. Out of 60 cases, 46 (77%) were male and 39 (65%) had diabetes. Out of 60 enrolled MHE cases, 16 (27%) had Child-Turcotte-Pugh-A (CTP-A) score and 44 (73%) belonged to CTP-B & C category. Out of 60 MHE cases, 23 (38.3%) showed improvement in their MHE status based on normalization of psychometric tests and reduction of serum ammonia level to ≤32 µmol/L. Age, gender and diabetes were not associated with the response to lactulose therapy. Low baseline arterial pressure was significantly (p=0.003) associated with non-response to lactulose treatment. The mean baseline ammonia level was higher significantly among the non-responders compared to the responders (83.6±21.4 µmol/L vs 58.8±19.8 µmol/L, p<0.001). Compared to responders, low serum sodium and potassium and raised serum bilirubin levels of non-responders at baseline were found significantly (p<0.05) associated with non-response to one month of lactulose treatment. Initial hemoglobulin, peripheral leucocyte and platelet counts did not have any effect on the response to lactulose treatment in MHE cases. Conclusions:The status of MHE in patients with cirrhosis improved by one-month treatment with lactulose. Baseline low arterial pressure, hyperammonemia, hypokalemia and hyponatremia were major contributors to non-response to lactulose therapy. The findings of the study would be useful in treating patients of cirrhosis with MHE. IMC J Med Sci 2018; 12(1): 15-21
url http://www.imcjms.com/registration/journal_full_text/231
work_keys_str_mv AT shireenahmed factorsassociatedwithnonresponsetolactulosetherapyincirrhoticpatientswithminimalhepaticencephalopathy
AT mdgolamazam factorsassociatedwithnonresponsetolactulosetherapyincirrhoticpatientswithminimalhepaticencephalopathy
AT indrajitkumardatta factorsassociatedwithnonresponsetolactulosetherapyincirrhoticpatientswithminimalhepaticencephalopathy
AT mdnazmulhoque factorsassociatedwithnonresponsetolactulosetherapyincirrhoticpatientswithminimalhepaticencephalopathy
AT tareqmbhuiyan factorsassociatedwithnonresponsetolactulosetherapyincirrhoticpatientswithminimalhepaticencephalopathy
_version_ 1725234543326134272